<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="16" family="AkzidenzGroteskBE,BoldItalic" color="#000000"/>
	<fontspec id="font9" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font12" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font15" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Open Access<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="306" width="250" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/7/6/R1028<b>Available online</b></text>
<text top="735" left="569" width="23" height="8" font="font4" id="p1_t3" reading_order_no="67" segment_no="25" tag_type="text">R1028</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t4" reading_order_no="3" segment_no="2" tag_type="title">Vol 7 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="499" height="14" font="font7" id="p1_t6" reading_order_no="4" segment_no="3" tag_type="title">Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene</text>
<text top="120" left="57" width="470" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title">amplification and overexpression: immunohistochemical and<b>Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene </b></text>
<text top="138" left="57" width="322" height="14" font="font7" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title">chromogenic in situ hybridization analysis<b>amplification and overexpression: immunohistochemical and </b></text>
<text top="155" left="57" width="499" height="12" font="font9" id="p1_t9" reading_order_no="7" segment_no="4" tag_type="text">Jorge S Reis-Filho 1,2,3 *, Fernanda Milanezi 2,3 *, Silvia Carvalho 2,3 *, Pete T Simpson 4 , Dawn Steele 1 ,<b>chromogenic </b></text>
<text top="171" left="57" width="480" height="12" font="font9" id="p1_t10" reading_order_no="8" segment_no="4" tag_type="text">Kay Savage 1 , Maryou BK Lambros 1 , Emilio M Pereira 5 , Jahn M Nesland 6 , Sunil R Lakhani 4 and<i><b>in situ </b></i></text>
<text top="187" left="57" width="108" height="12" font="font9" id="p1_t11" reading_order_no="9" segment_no="4" tag_type="text">Fernando C Schmitt 2<b>hybridization analysis</b></text>
<text top="221" left="57" width="321" height="7" font="font3" id="p1_t12" reading_order_no="10" segment_no="5" tag_type="text">1 The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK</text>
<text top="230" left="57" width="333" height="8" font="font3" id="p1_t13" reading_order_no="11" segment_no="6" tag_type="text">2 IPATIMUP – Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal</text>
<text top="240" left="57" width="397" height="7" font="font3" id="p1_t14" reading_order_no="12" segment_no="7" tag_type="text">3 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal</text>
<text top="249" left="57" width="494" height="8" font="font3" id="p1_t15" reading_order_no="13" segment_no="8" tag_type="text">4 Molecular &amp; Cellular Pathology, Mayne Medical School, University of Queensland, Queensland Institute of Medical Research and Royal Brisbane</text>
<text top="259" left="57" width="145" height="7" font="font3" id="p1_t16" reading_order_no="14" segment_no="8" tag_type="text">and Women's Hospital, Brisbane, Australia</text>
<text top="268" left="57" width="164" height="8" font="font3" id="p1_t17" reading_order_no="15" segment_no="9" tag_type="text">5 Laboratório Salomão &amp; Zoppi, São Paulo, Brazil</text>
<text top="278" left="57" width="249" height="7" font="font3" id="p1_t18" reading_order_no="16" segment_no="10" tag_type="text">6 The Norwegian Radium Hospital, University of Oslo, Montebello, Norway</text>
<text top="290" left="57" width="74" height="8" font="font3" id="p1_t19" reading_order_no="17" segment_no="11" tag_type="text">* Contributed equally</text>
<text top="307" left="57" width="202" height="7" font="font3" id="p1_t20" reading_order_no="18" segment_no="12" tag_type="text">Corresponding author: Jorge S Reis-Filho, jorgerf@icr.ac.uk</text>
<text top="325" left="57" width="495" height="7" font="font3" id="p1_t21" reading_order_no="19" segment_no="13" tag_type="text">Received: 17 Jul 2005 Revisions requested: 31 Aug 2005 Revisions received: 12 Sep 2005 Accepted: 29 Sep 2005 Published: 25 Oct 2005</text>
<text top="344" left="57" width="252" height="7" font="font11" id="p1_t22" reading_order_no="20" segment_no="14" tag_type="text">Breast Cancer Research 2005, 7 :R1028-R1035 (DOI 10.1186/bcr1341)</text>
<text top="354" left="57" width="265" height="7" font="font3" id="p1_t23" reading_order_no="21" segment_no="15" tag_type="text">This article is online at: http://breast-cancer-research.com/content/7/6/R1028</text>
<text top="364" left="57" width="187" height="7" font="font3" id="p1_t24" reading_order_no="22" segment_no="16" tag_type="text">© 2005 Reis-Filho et al .; licensee BioMed Central Ltd.</text>
<text top="374" left="57" width="495" height="7" font="font3" id="p1_t25" reading_order_no="23" segment_no="17" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/</text>
<text top="384" left="57" width="426" height="7" font="font3" id="p1_t26" reading_order_no="24" segment_no="17" tag_type="text">2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="414" left="57" width="43" height="10" font="font12" id="p1_t27" reading_order_no="25" segment_no="18" tag_type="title">Abstract</text>
<text top="434" left="57" width="240" height="8" font="font13" id="p1_t28" reading_order_no="26" segment_no="19" tag_type="text">Introduction Metaplastic breast carcinomas constitute a</text>
<text top="444" left="57" width="240" height="8" font="font14" id="p1_t29" reading_order_no="27" segment_no="19" tag_type="text">heterogeneous group of neoplasms, accounting for less than</text>
<text top="455" left="57" width="240" height="8" font="font14" id="p1_t30" reading_order_no="28" segment_no="19" tag_type="text">1% of all invasive mammary carcinomas. Approximately 70–</text>
<text top="465" left="57" width="240" height="8" font="font14" id="p1_t31" reading_order_no="29" segment_no="19" tag_type="text">80% of metaplastic breast carcinomas overexpress the</text>
<text top="476" left="57" width="240" height="8" font="font14" id="p1_t32" reading_order_no="30" segment_no="19" tag_type="text">epidermal growth factor receptor (EGFR). Human epidermal</text>
<text top="486" left="57" width="240" height="8" font="font14" id="p1_t33" reading_order_no="31" segment_no="19" tag_type="text">growth factor receptor (HER)2 and EGFR have attracted much</text>
<text top="497" left="57" width="241" height="8" font="font14" id="p1_t34" reading_order_no="32" segment_no="19" tag_type="text">attention in the medical literature over the past few years owing</text>
<text top="507" left="57" width="240" height="8" font="font14" id="p1_t35" reading_order_no="33" segment_no="19" tag_type="text">to the fact that humanized monoclonal antibodies against HER2</text>
<text top="518" left="57" width="240" height="8" font="font14" id="p1_t36" reading_order_no="34" segment_no="19" tag_type="text">and therapies directed against the extracellular ligand-binding</text>
<text top="528" left="57" width="240" height="8" font="font14" id="p1_t37" reading_order_no="35" segment_no="19" tag_type="text">domain or the intracellular tyrosine kinase domain of EGFR have</text>
<text top="539" left="57" width="240" height="8" font="font14" id="p1_t38" reading_order_no="36" segment_no="19" tag_type="text">proven successful in treating certain types of human cancer. We</text>
<text top="549" left="57" width="240" height="8" font="font14" id="p1_t39" reading_order_no="37" segment_no="19" tag_type="text">investigated whether HER2 and EGFR overexpression was</text>
<text top="560" left="57" width="240" height="8" font="font14" id="p1_t40" reading_order_no="38" segment_no="19" tag_type="text">present and evaluated gene amplification in a series of</text>
<text top="570" left="57" width="118" height="8" font="font14" id="p1_t41" reading_order_no="39" segment_no="19" tag_type="text">metaplastic breast carcinomas.</text>
<text top="591" left="57" width="241" height="8" font="font13" id="p1_t42" reading_order_no="40" segment_no="23" tag_type="text">Method Twenty-five metaplastic breast carcinomas were</text>
<text top="602" left="57" width="240" height="8" font="font14" id="p1_t43" reading_order_no="41" segment_no="23" tag_type="text">immunohistochemically analyzed using a monoclonal antibody</text>
<text top="612" left="57" width="240" height="8" font="font14" id="p1_t44" reading_order_no="42" segment_no="23" tag_type="text">(31G7) for EGFR and two antibodies for HER2 (Herceptest and</text>
<text top="623" left="57" width="240" height="8" font="font14" id="p1_t45" reading_order_no="43" segment_no="23" tag_type="text">CB11) and scored using the Herceptest scoring system. Gene</text>
<text top="633" left="57" width="241" height="8" font="font14" id="p1_t46" reading_order_no="44" segment_no="23" tag_type="text">amplification was evaluated by chromogenic in situ hybridization</text>
<text top="644" left="57" width="240" height="8" font="font14" id="p1_t47" reading_order_no="45" segment_no="23" tag_type="text">using Zymed Spot-Light EGFR and HER2 amplification probe.</text>
<text top="434" left="315" width="240" height="8" font="font14" id="p1_t48" reading_order_no="46" segment_no="20" tag_type="text">The results were evaluated by bright field microscopy under</text>
<text top="444" left="315" width="118" height="8" font="font14" id="p1_t49" reading_order_no="47" segment_no="20" tag_type="text">40× and 63× objective lenses.</text>
<text top="465" left="315" width="241" height="8" font="font13" id="p1_t50" reading_order_no="48" segment_no="21" tag_type="text">Results Nineteen (76%) metaplastic breast carcinomas</text>
<text top="476" left="315" width="240" height="8" font="font14" id="p1_t51" reading_order_no="49" segment_no="21" tag_type="text">exhibited EGFR ovexpression, and among these EGFR</text>
<text top="486" left="315" width="240" height="8" font="font14" id="p1_t52" reading_order_no="50" segment_no="21" tag_type="text">amplification (defined either by large gene clusters or &gt;5<i>Breast Cancer Research</i></text>
<text top="497" left="315" width="241" height="8" font="font14" id="p1_t53" reading_order_no="51" segment_no="21" tag_type="text">signals/nucleus in &gt;50% of neoplastic cells) was detected in</text>
<text top="507" left="315" width="240" height="8" font="font14" id="p1_t54" reading_order_no="52" segment_no="21" tag_type="text">seven cases (37%): three carcinomas with squamous<b>7</b></text>
<text top="518" left="315" width="240" height="8" font="font14" id="p1_t55" reading_order_no="53" segment_no="21" tag_type="text">differentiation and four spindle cell carcinomas. One case</text>
<text top="528" left="315" width="240" height="8" font="font14" id="p1_t56" reading_order_no="54" segment_no="21" tag_type="text">exhibited HER2 overexpression of grade 2+ (&gt;10% of cells with<a href="http://breast-cancer-research.com/content/7/6/R1028">This article is online at: http://breast-cancer-research.com/content/7/6/R1028</a></text>
<text top="539" left="315" width="240" height="8" font="font14" id="p1_t57" reading_order_no="55" segment_no="21" tag_type="text">weak to moderate complete membrane staining), but HER2</text>
<text top="549" left="315" width="140" height="8" font="font14" id="p1_t58" reading_order_no="56" segment_no="21" tag_type="text">gene amplification was not detected.<i> et al</i></text>
<text top="570" left="315" width="241" height="8" font="font13" id="p1_t59" reading_order_no="57" segment_no="22" tag_type="text">Conclusion Metaplastic breast carcinomas frequently</text>
<text top="581" left="315" width="240" height="8" font="font14" id="p1_t60" reading_order_no="58" segment_no="22" tag_type="text">overexpressed EGFR, which was associated with EGFR gene<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/</a></text>
<text top="591" left="315" width="240" height="8" font="font14" id="p1_t61" reading_order_no="59" segment_no="22" tag_type="text">amplification in one-third of cases. Our findings suggest that<a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="602" left="315" width="240" height="8" font="font14" id="p1_t62" reading_order_no="60" segment_no="22" tag_type="text">some patients with metaplastic breast carcinomas might benefit<b>Abstract</b></text>
<text top="612" left="315" width="240" height="8" font="font14" id="p1_t63" reading_order_no="61" segment_no="22" tag_type="text">from novel therapies targeting EGFR. Because most<b>Introduction</b></text>
<text top="623" left="315" width="240" height="8" font="font14" id="p1_t64" reading_order_no="62" segment_no="22" tag_type="text">metaplastic breast carcinomas overexpress EGFR without gene</text>
<text top="633" left="315" width="240" height="8" font="font14" id="p1_t65" reading_order_no="63" segment_no="22" tag_type="text">amplification, further studies to evaluate EGFR activating</text>
<text top="644" left="315" width="94" height="8" font="font14" id="p1_t66" reading_order_no="64" segment_no="22" tag_type="text">mutations are warranted.</text>
<text top="724" left="57" width="498" height="7" font="font3" id="p1_t67" reading_order_no="65" segment_no="24" tag_type="footnote">CISH = chromogenic in situ hybridization; DFS = disease-free survival; EGFR = epidermal growth factor receptor; HER = human epidermal growth</text>
<text top="734" left="57" width="258" height="7" font="font3" id="p1_t68" reading_order_no="66" segment_no="24" tag_type="footnote">factor receptor; MBC = metaplastic breast carcinoma; OS = overall survival.</text>
</page>
</pdf2xml>
